CME/CE

CME/CE

By ReachMDMedicine
Download on the App Store

CME/CE episodes

  • Advances in Minimally Invasive Screening for Lung Cancer
    Guest: Julie A. Barta, MD, ATSF
    Host: Peter J. Mazzone, MD, MPH, FCCP

    Lung cancer is most treatable when detected at early stages, yet fewer than 5% of eligible adults are screened using the recommended low-dose CT scan. Blood-based tests for early detection of lung cancer are in development. Join Dr. Peter Mazzone and Dr. Julie Barta as they discuss the latest data on these tests with potential to improve screening rates and outcomes in high-risk individuals.

    16 min
  • Is Gout Hiding in the Nephrology Clinic?
    Host: Abdul Abdellatif, MD, FASN
    Guest: Richard Johnson, MD

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • Gout Beyond the Joints: What’s the Hidden Danger?
    Host: Richard Johnson, MD

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    4 min
  • Center of the Target: Which Patients Are Most Likely to Develop Gout?
    Host: Richard Johnson, MD
    Guest: Abdul Abdellatif, MD, FASN

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • Is Managing Gout in the Nephrology Clinic a Challenge?
    Host: Richard Johnson, MD
    Guest: Abdul Abdellatif, MD, FASN

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • Treat or Refer: Who Is Responsible for Managing Gout?
    Host: John K. Botson, MD, RPh
    Guest: Abdul Abdellatif, MD, FASN

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • Can You Manage Patients With Uncontrolled Gout More Effectively?
    Host: Abdul Abdellatif, MD, FASN
    Guest: John K. Botson, MD, RPh

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • What’s New About Gout? Nephrology Perspective
    Host: Abdul Abdellatif, MD, FASN
    Guest: Richard Johnson, MD

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • What’s New About Gout? Rheumatology Perspective
    Host: Richard Johnson, MD
    Guest: John K. Botson, MD, RPh

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min
  • What Are the Emerging Therapies for Managing Gout?
    Host: Richard Johnson, MD
    Guest: John K. Botson, MD, RPh

    This activity is no longer available for continuing education credit.

    Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

    5 min

About CME/CE

From the publisher's feed

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes,…